Daohong Zhou

This paper develops an AI-driven drug discovery framework for NALCN channelopathy, identifying aprepitant as a lead therapeutic candidate through HTS, structural modeling, and experimental validation.

This study shows that clearing senescent cells with 753b improves bone marrow aging by restoring HSC function and niche balance.

This study identifies TMEM127 as a critical regulator of the MHC-I degradation complex by modulating WWP2 activity, offering a target for enhancing antigen presentation in cancer immunology.

This paper shows that combining BCL-xL PROTAC and mTOR inhibitor with KRASG12D inhibitor enhances apoptosis and overcomes resistance in PDAC.

This study identifies NF2 as a critical tumor suppressor in PDAC, showing its role in promoting invasive behavior, enhancing cell fitness under stress, and contributing to drug resistance.

This study identifies OXPHOS-high quiescent triple-negative breast cancer cells that survive chemotherapy and depend on BCL-XL for survival, showing that targeting BCL-XL enhances chemotherapy efficacy.

This paper introduces a fluorescent assay to quantify ubiquitination kinetics in targeted protein degradation, enabling measurement of degrader and ligase affinities and ternary complex activity.

This study shows that combining radiation with Bcl-xL inhibition reduces tumor growth in preclinical models of H3K27M-altered diffuse midline glioma.

This paper evaluates a dual BCL-xL/BCL-2 degrader, 753b, showing it effectively reduces tumor viability and growth in SCLC models while avoiding platelet toxicity seen with navitoclax.

DyScore improves protein-ligand binding prediction by incorporating dynamic features into a boosting model, achieving better performance than existing methods.